Prabhudas Lilladher recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 602 in its research report dated January 28, 2021.

Buy Sun Pharma; target of Rs 740: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 740 in its research report dated January 30, 2021.

Sun Pharma: Sustained traction in speciality to be a re-rating driver

Sun Pharma's India business is expected to gain traction as sub-chronic and acute therapies pick up with the opening up of clinics/OPDs. This is likely to be fully backed by the field force where the expansion has recently been completed

Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate

We believe dominance of profit/royalty-sharing aspect in the business model distinguishes Gland Pharma from other contract manufacturers

Buy Sun Pharmaceutical Industries: target of Rs 660 : Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 660 in its research report dated December 14, 2020.

Buy Sun Pharmaceutical Industries; target of Rs 585: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 585 in its research report dated November 04, 2020.

Buy Sun Pharmaceutical Industries; target of Rs 597: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 597 in its research report dated November 04, 2020.

Buy Sun Pharmaceutical Industries: target of Rs 612: Sharekhan

Sharekhan is bullish on Sun Pharmaceutical Industries recommended buy rating on the stock with a target price of Rs 612 in its research report dated November 03, 2020.

Sun Pharma: Traction in select speciality comes as a surprise

Though valuation is still not inexpensive, we see improved trade sentiment for Sun Pharma post results. Sustained traction in speciality will be a key re-rating driver

Reduce Sun Pharmaceutical Industries; target of Rs 476: Prabhudas Lilladher

Prabhudas Lilladher recommended Reduce rating on Sun Pharmaceutical Industries with a target price of Rs 476 in its research report dated October 30, 2020.

Buy Sun Pharmaceuticals; target of Rs 660: Dolat Capital

Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 660 in its research report dated September 21, 2020.

Buy Sun Pharmaceutical Industries; target of Rs 625: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 625 in its research report dated August 02, 2020.

Buy Sun Pharmaceuticals; target of Rs 571: Dolat Capital

Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 571 in its research report dated August 01, 2020.

Buy Sun Pharma; target of Rs 619 KRChoksey

KRChoksey is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 619 in its research report dated August 07, 2020.

Hold Sun Pharma; target of Rs 542: Emkay Global Financial

Emkay Global Financial recommended hold rating on Sun Pharma with a target price of Rs 542 in its research report dated July 31, 2020.

Reduce Sun Pharmaceutical Industries; target of Rs 479: Prabhudas Lilladher

Prabhudas Lilladher recommended reduce rating on Sun Pharmaceutical Industries with a target price of Rs 479 in its research report dated August 02, 2020.

Hold Sun Pharmaceuticals Industries; target of Rs 575: Sharekhan

Sharekhan recommended Hold rating on Sun Pharmaceuticals Industries with a target price of Rs 575 in its research report dated July 31, 2020.

Buy Sun Pharma; target of Rs 625: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 625 in its research report dated August 01, 2020.

Hold Sun Pharmaceutical Industries; target of Rs 479: Prabhudas Lilladher

Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 479 in its research report dated July 31, 2020.

Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

What adds to the Sun Pharma's investment case is the prospect for US specialty. The management hopes to achieve EBITDA break-even for a few products next fiscal

Buy Sun Pharmaceuticals; target of Rs 530: Dolat Capital

Dolat Capital is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 530 in its research report dated June 11, 2020.

Buy Sun Pharmaceutical Industries; CMP of Rs 494.25: Equity99

Equity99 is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a CMP price of Rs 494.25 in its research report dated June 08, 2020.

Buy Sun Pharmaceutical Industries; target of Rs 540: ICICI Direct

ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 540 in its research report dated May 28, 2020.

Hold Sun Pharmaceutical Industries target of Rs 510: Sharekhan

Sharekhan recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 510 in its research report dated May 27, 2020.

Buy Sun Pharma ; target of Rs 525: Motilal Oswal

Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 525 in its research report dated May 27, 2020.